FindTrial
Sign In

An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored remibrutinib study and are judged by the investigator to benefit from continued treatment with remibrutinib

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-524078-40-00
Enrollment
48
Registered
2026-05-20
Start date
Unknown
Completion date
Unknown
Last updated
2026-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Spontaneous Urticaria

Brief summary

Serious adverse events (SAEs), adverse events (AEs)

Interventions

DRUGLOU064

Sponsors

Novartis Pharma AG
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Serious adverse events (SAEs), adverse events (AEs)—

Outcome results

None listed

Source: EU CTIS · Data processed: May 22, 2026